SUN CITY

Jan 8, 2025 | alzres.biomedcentral.com | SUN CITY |Vrije Universiteit Amsterdam

evoke (NCT04777396) and evoke+ (NCT04777409) are randomized (1:1), double-blind, placebo-controlled, parallel-group trials investigating the efficacy and safety of oral semaglutide versus placebo in participants with early-stage symptomatic AD (Fig. 1). The description in this paper is based on the protocol version 10.

Jan 6, 2025 | thelancet.com | Nicholas Ashton |SUN CITY

In 2014, when eBioMedicine launched its first issue, in vivo biomarkers to detect the hallmarks of Alzheimer’s disease (AD) were entirely restricted to position emission tomography (PET) and cerebrospinal fluid (CSF). There was certainly limited enthusiasm that a comparable determination about AD pathology or neurodegeneration could be made from an easily accessible biofluid such as blood.

Dec 2, 2024 | link.springer.com | Anna Katharina |Civin Laboratory |SUN CITY

AbstractThe formation of amyloid-β (Aβ) aggregates in brain is a neuropathological hallmark of Alzheimer’s disease (AD). However, there is mounting evidence that Aβ also plays a pathogenic role in other types of dementia and that specific post-translational Aβ modifications contribute to its pathogenic profile. The objective of this study was to test the hypothesis that distinct types of dementia are characterized by specific patterns of post-translationally modified Aβ variants.